Medication development in opioid addiction: Meaningful clinical end points.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 29593105.
- Also identified by DOI 10.1126/scitranslmed.aan2595.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The FDA's "abstinence" outcome measure for approval of new medications to treat opioid-use disorders has been difficult to achieve; developing and validating alternative meaningful outcomes could facilitate drug development.
Medical subject headings
- Opioid-Related Disorders